Theresia Tabe
Psychiatric/Mental Health, Adult · Plano, TXNPI 1861038234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 552 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health, adult clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 552 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- Corium, LLC$542
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$540
- Sunovion Pharmaceuticals Inc.$536
- plus $4K from 23 others
What the payments were for
- Food & beverage$10,483100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 87 | $1,642 |
| AbbVie | 92 | $1,555 |
| Alkermes, Inc. | 75 | $1,485 |
| Corium, LLC | 29 | $542 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $540 |
| Sunovion Pharmaceuticals Inc. | 28 | $536 |
| Vanda Pharmaceuticals Inc. | 23 | $467 |
| Axsome Therapeutics, Inc. | 20 | $467 |
| Lundbeck LLC | 25 | $447 |
| Almatica Pharma LLC | 29 | $405 |
| Teva Pharmaceuticals USA, Inc. | 19 | $379 |
| Tris Pharma Inc | 17 | $365 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $234 |
| Johnson & Johnson | 10 | $213 |
| Merck | 8 | $172 |
| Bausch Health US, LLC | 8 | $158 |
| Neos Therapeutics, LP | 9 | $138 |
| Noven Therapeutics, LLC | 7 | $137 |
| Harmony Biosciences LLC | 5 | $112 |
| E.r. Squibb & Sons, L.L.C. | 4 | $103 |
| Neurocrine Biosciences, Inc. | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Ironshore Pharmaceuticals Inc. | 3 | $63 |
| Inspire Medical Systems, Inc. | 3 | $62 |
| Eisai Inc. | 2 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Indivior Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,511 in reported general payments places this provider in the 95th percentile of 22 psychiatric/mental health, adult providers in Texas.
See all psychiatric/mental health, adult providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 32 | $65,201 |
| VraylarCariprazine Hcl | 43 | $62,722 |
| Aripiprazole | 78 | $2,847 |
| Duloxetine Hcl | 105 | $1,771 |
| Lamotrigine | 101 | $1,390 |
| Quetiapine Fumarate | 73 | $1,140 |
| Bupropion XlBupropion Hcl | 72 | $907 |
| Trazodone Hcl | 170 | $851 |
| Alprazolam | 157 | $841 |
| Prazosin Hcl | 31 | $802 |
| Clonazepam | 114 | $796 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 22 | $648 |
| Oxcarbazepine | 27 | $632 |
| Risperidone | 31 | $498 |
| Mirtazapine | 50 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,642 | $65,20132 claims |
| AbbVieVraylar | $1,555 | $62,72243 claims |
| Almatica Pharma LLCSertraline Hcl | $405 | $30867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 psychiatric/mental health, adult providers in Texas.
Other psychiatric/mental health, adult in Plano
- Ricardo GonzalezEl Paso$15K
- Hilda SolisPharr$7K
- Lorraine PapaAustin$2K
- Robert RobertsonParis$1K
- Tomas RodriguezHouston$315
- Helena MendinHouston$284
- Mary GlenneyAustin$273
- Aisha KhanWebster$259
- Stephen MinotAustin$224
- Bernadette EtoamaHouston$219
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.